By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > SSRI antidepressant > Fluvoxamine

Fluvoxamine

GMJ
Last updated: 02/06/2026 14:31
By
Prof. Giorgi Pkhakadze
Share
4 Min Read
SHARE
3 min read|574 words

Fluvoxamine Drug Profile

What is Fluvoxamine?

Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) antidepressant medication primarily used to treat obsessive-compulsive disorder and depression. It belongs to the class of medications that work by increasing serotonin levels in the brain. Fluvoxamine was one of the first SSRI medications developed and has been widely used since the 1980s.

Uses

Fluvoxamine is approved and commonly prescribed for several mental health conditions:

  • Obsessive-Compulsive Disorder (OCD): The primary FDA-approved indication, helping reduce intrusive thoughts and compulsive behaviors
  • Major Depressive Disorder: Treatment of depression symptoms including persistent sadness, loss of interest, and mood changes
  • Social Anxiety Disorder: Reducing excessive fear and avoidance of social situations
  • Panic Disorder: Prevention and treatment of panic attacks and associated anxiety
  • Post-Traumatic Stress Disorder (PTSD): Off-label use for managing trauma-related symptoms

How it works

Fluvoxamine works by blocking the reuptake of serotonin in the brain, which increases the amount of this neurotransmitter available between nerve cells. Serotonin plays a crucial role in regulating mood, anxiety, and obsessive thoughts. By maintaining higher serotonin levels, fluvoxamine helps improve symptoms of depression, OCD, and anxiety disorders over time.

Side effects

Common side effects include:

Submit Your Paper
GMJ_Submit_Banner
  • Nausea and stomach upset
  • Drowsiness or fatigue
  • Headache
  • Dizziness
  • Dry mouth
  • Constipation or diarrhea
  • Sleep disturbances or insomnia
  • Sexual dysfunction or decreased libido

Serious side effects requiring immediate medical attention:

  • Suicidal thoughts or behaviors, especially in young adults
  • Serotonin syndrome (fever, muscle rigidity, confusion, rapid heart rate)
  • Severe allergic reactions with rash, swelling, or difficulty breathing
  • Unusual bleeding or bruising
  • Seizures or convulsions

Warnings and precautions

  • Black Box Warning: Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults under 25, especially during the first few months of treatment
  • Pregnancy considerations: Category C medication that should only be used when benefits outweigh risks; may cause withdrawal symptoms in newborns
  • Liver function: Use with caution in patients with liver disease as fluvoxamine is extensively metabolized by the liver
  • Discontinuation: Should be tapered gradually rather than stopped abruptly to avoid withdrawal symptoms
  • Bipolar disorder: May trigger manic episodes in patients with undiagnosed bipolar disorder

Interactions

Fluvoxamine has numerous significant drug interactions due to its effects on liver enzymes:

  • MAO inhibitors: Can cause dangerous serotonin syndrome; require 14-day washout period
  • Warfarin: Fluvoxamine increases warfarin levels, raising bleeding risk
  • Theophylline: Significantly increases theophylline levels, potentially causing toxicity
  • Clozapine: Dramatically increases clozapine levels, requiring dose adjustments
  • Benzodiazepines: Enhances effects of diazepam and alprazolam, increasing sedation
  • Triptans: Increased risk of serotonin syndrome when combined with migraine medications
  • NSAIDs and aspirin: May increase bleeding risk, especially gastrointestinal bleeding
  • St. John’s Wort: Herbal supplement that increases serotonin syndrome risk

Check interactions with the GMJ Interaction Checker

Dosage

Typical adult dosing varies by condition and should always be determined by a healthcare provider:

  • Obsessive-Compulsive Disorder: Starting dose 50mg daily at bedtime, may increase to 100-300mg daily as tolerated
  • Depression: Initial dose 50mg daily, typically increased to 100-200mg daily in divided doses
  • Maximum dose: Generally should not exceed 300mg daily for most patients

Doses are typically started low and gradually increased to minimize side effects. The medication should be taken with food to reduce stomach upset. Extended-release formulations may be taken once daily, while immediate-release forms are often divided into multiple daily doses.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Fluvoxamine." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/fluvoxamine/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Mental health therapies judged by wrong research standards, Manchester analysis reveals

New University of Manchester analysis argues psychological therapies are inappropriately evaluated using…

Evidence review: Which supplements older adults actually need and which ones to avoid

New evidence shows older adults benefit more from targeted supplementation for specific…

Traditional Chinese herb shows promise for androgenetic alopecia treatment

Traditional Chinese herb Polygonum multiflorum shows promise for treating androgenetic alopecia through…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Citalopram

By
Prof. Giorgi Pkhakadze
02/06/2026

Paroxetine

By
Prof. Giorgi Pkhakadze
02/06/2026

Escitalopram

By
Prof. Giorgi Pkhakadze
02/06/2026

Fluoxetine

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up